Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario with manufacturing facilities located in Varennes, Quebec and Wanzleben, Germany, and a research and development facility in San Diego, California. Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. The Company develops drugs based on two technology platforms: transdermal drug delivery and immune system regulation. Nuvo markets two products Pennsaid®, a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis of the knee and Oxoferin™, a topical wound healing agent. In June 2009, Nuvo entered into a license and development agreement with Mallinckrodt Inc., a subsidiary of Covidien (NYSE:COV), a leading global provider of healthcare products, granting it exclusive rights to market and sell Pennsaid, and its follow-on product, Pennsaid Plus, in the United States.
There is no investment information
No recent news or press coverage available for fqubed, Inc..